<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Czech and Slovak Ophthalmology</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">393</article-id>
      <article-categories>
        <subj-group>
          <subject>Original article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Diabetic Macular Edema – New Possibilities of the Treatment</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Studnička</surname>
            <given-names>Jan</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9911-4379</contrib-id>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="electronic">
        <day>7</day>
        <month>5</month>
        <year>2012</year>
      </pub-date>
      <issue>2</issue>
      <elocation-id>3</elocation-id>
      <abstract>
        <p>The article summarizes data from the literature about new possibilities of the diabetic macular edema treatment. Comparing intravitreal application of triamcinolone and laser photocoagulation, the better effect of the laser treatment with its lower side effects was proven. In combined treatment of triamcinolone and laser photocoagulation comparing with the laser monotherapy, no better effect of the combined therapy was proven. The intravitreal implant releasing fluocinolone acetonide significantly improved the bestcorrectedvisual acuity (BCVA), but caused cataract progression and elevation of the intraocular pressure. Intravitreal application of ranibizumab significantly improved BCVA in the monotherapy, and in the combination with the retinal laser photocoagulation did as well. Intravitreal application of bevacizumab significantly improved BCVA, but its use is off-label only. Aflibercept is in the final stage of clinical trails.</p>
      </abstract>
      <kwd-group>
        <kwd>laser photocoagulation</kwd>
        <kwd>triamcinolon</kwd>
        <kwd>fluocinolon acetonide</kwd>
        <kwd>ranibizumab</kwd>
        <kwd>bevacizumab</kwd>
        <kwd>aflibercept</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
